DocumentsDate added
Original article
Sharmila 1 MD (OBG), Sendhil Coumary.A1* MD, DNB, MNAMS (OBG), Lopamudra B John1† MD, DNB (OBG), Seetesh Ghose 1¥ MD, FICOG
Affiliation:-
1Assisstant Professor, *1Professor, 1†Associate Professor, 1¥Professor And Head Of Department, Department Of Obstetrics And Gynaecology, Mahatma Gandhi Medical College And Research Institute Pillaiyarkuppam Puducherry- 607402, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Obstetrics and Gynaecology, Mahatma Gandhi Medical College and Research Institute, Puducherry, India
Address reprint requests to
Dr. Sendhil Coumary. A,
Department of Obstetrics and Gynaecology, Mahatma Gandhi Medical College And Research Institute, Pillaiyarkuppam, Puducherry, India-607402
Article citation:
Sharmila ,Coumary SA,John LB,Ghose S. Effectiveness of Intravenous Iron Sucrose among SouthIndian Antenatal Women. J Pharm Biomed Sci. 2014; 04(09):936-940. Available at www.jpbms.info
ABSTRACT
Objectives: The study aims to evaluate the safety and efficacy of intravenous iron sucrose among south indian antenatal women with moderate iron deficiency anaemia in the second trimester not responding to oral iron.
Methods: The study was a prospective interventional study conducted in the department of obstetrics and gynaecology at MGMCRI, Pondicherry, South India. During a study period of 18 months starting from December 2011, a total of 61 antenatal women were included in the study. 32 received intravenous iron sucrose in divided doses, as they did not respond well to oral iron. Haemoglobin, PCV and serum ferritin were measured before and after intra venous sucrose. The results were tabulated and analysed.
Results: After oral iron therapy the mean haemoglobin was 8.97 ± 0.80 gm%, the mean PCV was 28.16 ± 2.6, and the mean serum ferritin was 13.32 ± 2.49 micrograms respectively. After IV iron sucrose therapy the mean haemoglobin was 10.15 ± 0.36, the mean PCV was 31.5± 2.10 and the mean serum ferritin was 44.09± 7.02 respectively. There was a statistically significant difference in the rise of mean haemoglobin, PCV and serum ferritin after therapy with iron sucrose. There were no significant side effects related to intravenous iron sucrose therapy.
Conclusion: Iron sucrose is safe and effective without any serious side effects in correcting the iron deficiency anemia in pregnancy among those who are not responding or intolerant to oral iron.
KEYWORDS: Iron sucrose; iron deficiency anemia; antenatal women.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
REFERENCES
1.Nutritional anemia during pregnancy in non industrialised countries in Progress in Obstetrics and Gynaecology 15. Studd J, Tan S L, Frank A. Chervenak. 2003; 8 (1): 103-121.
2.Aykut Barut, Mehmet Harma Intravenous iron treatment for iron deficiency anemia in pregnancy. J Turkish-German Gynecol Assoc 2009;10: 109-15
3.Alhossain A. Khalafallah, Amanda E. Dennis Iron deficiency anemia in pregnancy and postpartum : pathophysiology and effect of oral versus intravenous iron therapy. Journal of pregnancy Volume 2012 doi:10.1155/2012/630519
4.Arnoff GR, Bennett WM, Blumenthal S et al. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int 2004;66:1193-98
5.Ragip A Al, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, and Haberal A. Intravenous versus oral Iron in the treatment of anemia in pregnancy. The American College of Obstetricians and Gynaecologists, 2005; 106(6) : 1335-40.
6.Naz N, Mashoori R G, Zehra T, Chaudhry A, Laghari J. Intravenous Iron Sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy. Medical Channel 2008 Mar ; 14(1): 55-58.
7.Shafi D, Purandare SV, Sathe AV. Iron deficiency anemia in pregnancy: intravenous versus oral route. J Obstet Gynaecol India. 2012 Jun;62(3):317-21. doi: 10.1007/s13224-012-0222-0. Epub 2012 Aug 1.
8.Deepti S, Sunetra I, Sindhu B, Amreen S. Effectiveness of Intravenous Iron Sucrose in Management Of Iron Deficient Anemia of Pregnancy at Rural Hospital Set Up. Journal of Obstetrics and Gynaecology of India 2012 Apr; 62(2): 154-157.
Copyright © 2014 Sharmila ,Coumary SA,John LB,Ghose S. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Review article
Mukund Joshi1,*, Kuldip Singh Sodhi2, Rajesh Pandey2, Jasbir Singh2, Subhash Goyal3
Affiliation:-
1(MSc Medical Biochemistry),Department of Biochemistry,MMIMSR, Mullana, Ambala, Haryana, India.
2Professor,Department of Biochemistry,MMIMSR, Mullana, Ambala, Haryana, India.
3Professor, Department of Surgery, MMIMSR, Mullana, Ambala, Haryana, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Biochemistry, MMIMSR, Mullana, Ambala, Haryana, India
Address reprint requests to
Mukund Joshi.
Department of Biochemistry,
MMIMSR, Mullana, Ambala, Haryana, India
Article citation:
Joshi M, Sodhi KS, Pandey R, Singh J, Goyal S. Serum uric acid and Cardiovascular disease. J Pharm Biomed Sci. 2014; 04(11):972-983. Available at www.jpbms.info
ABSTRACT
A substantial body of epidemiological and experimental evidence suggests the significance of serum uric acid as an important and independent risk factor of cardiovascular and renal diseases especially in patients with diabetes mellitus, hypertension or heart failure. Elevated serum uric acid is highly predictive of mortality in patients with heart failure or coronary artery disease and of cardiovascular events in patients with diabetes. Moreover patients with hypertension and hyperuricemia have a 3- to 5-fold increased risk of experiencing coronary artery disease or cerebrovascular disease compared with patients with normal uric acid levels. Although the mechanisms by which uric acid may play pathogenetic role in cardiovascular disease is unclear. Hyperuricemia is associated with deleterious effects on endothelial dysfunction, oxidative metabolism, platelet adhesiveness, hemorheology, and aggregation. Xanthine oxidase inhibitors (e.g., allopurinol) or a variety of uricosuric agents (e.g., probenecid, sulfinpyrazone, benzbromarone, and benziodarone) can lower elevated uric acid levels but it is unknown whether these agents reversibly impact cardiovascular outcomes. Hyperuricemia will become then a meaningful target for the prevention and treatment of cardiovascular disease. Overall, serum uric acid may be a powerful tool to help stratify risk for cardiovascular disease. At the very least, it should be carefully considered when evaluating overall cardiovascular risk.
KEYWORDS: Hypertension; uric acid; gout; allopurinol; coronary heart disease.
REFERENCES
1.Skak-Nielsen H. Torp-Pedersen C, Finer N, Caterson ID, Van Gaal L, James WP, et al. Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals. PLoS One. 2013; 8(3): e59121.
2.Emmerson BT. The management of gout. N Engl J Med. 1996; 334(7): 445-51.
3.Steele TH. Hyperuricemic nephropathies. Nephron. 1999; 81(1): 45-9
4.Yeldandi AV, Patel YD, Liao M, Kao FT, Rao MS, Reddy JK, et al. Localization of the human urate oxidase gene (UOX) to 1p22. Cytogenet Cell Genet. 1992; 61(2): 121-2.
5.Wu XW, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol. 1992; 34(1): 78-84.
6.Kohn PM, Prozan GB. Hyperuricemia; relationship to hypercholesteremia and acute myocardial infarction. J Am Med Assoc. 1959; 170(16): 1909-12.
7.Beard JT 2nd. Serum uric acid and coronary heart disease. Am Heart J. 1983; 106(2): 397-400.
8.Torun M, Yardim S, Simsek B, Burgaz S. Serum uric acid levels in cardiovascular diseases. J Clin Pharm Ther. 1998; 23(1): 25-9.
9.Waring WS, Webb DJ, Maxwell SR. Uric acid as a risk factor for cardiovascular disease. QJM. 2000a; 93(11): 707-13.
10.Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension. 1999; 34(1): 144-50.
11.Ward HJ. Uric acid as an independent risk factor in the treatment of hypertension. Lancet. 1998; 352(9129): 670-1.
12.Liese AD, Hense HW, Löwel H, Döring A, Tietze M, Keil U. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology. 1999; 10(4): 391-7
13.Bengtsson C, Lapidus L, Stendahl C, Waldenström J. Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand. 1988; 224(6): 549-55
14.Lehto S, Niskanen L, Rönnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke. 1998; 29(3): 635-9.
15.Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart. 1997; 78(2): 147-53.
16.Coronaty heart project research group; Serum uric acid: its association with other risk factors and with mortality in coronary heart disease. J Chronic Dis. 1976; 29(9): 557-69.
17.Reunanen A, Takkunen H, Knekt P, Aromaa A. Hyperuricemia as a risk factor for cardiovascular mortality. Acta Med Scand Suppl. 1982; 668: 49-59.
18.Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999; 131(1): 7-13.
19.Iribarren C, Folsom AR, Eckfeldt JH, McGovern PG, Nieto FJ. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis Risk in Communities. Ann Epidemiol. 1996; 6(4): 331-40.
20.Reed DM, MacLean CJ, Hayashi T. Predictors of atherosclerosis in the Honolulu Heart Program. I. Biologic, dietary, and lifestyle characteristics. Am J Epidemiol. 1987; 126(2): 214-25.
21.Ames BN, Cathcart R, Schwiers E, and Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci 1981; 78: 6858–62.
22.Davies KJ, Sevanian A, Muakkassah-Kelly SF, and Hochstein P. Uric acidiron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J .1986; 235:747–754.
23.Nieto FJ, Iribarren C, Gross MD, Comstock GW, and Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000; 148:131–9.
24.De Scheerder IK, van de Kraay AM, Lamers JM, Koster JF, de Jong JW, Serruys PW. Myocardial malondialdehyde and uric acid release after short-lasting coronary occlusions during coronary angioplasty: potential mechanisms for free radical generation. Am J Cardiol 1991; 68: 392–5.
25.Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ., et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J. 1998; 19: 1814–22.
26.Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005; 16(12): 3553-62.
27.Johnson RJ., et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003; 41(6): 1183-90.
28.Costa F., et al. Intravascular source of adenosine during forearm ischemia in humans: implications for reactive hyperemia. Hypertension. 1999; 33(6): 1453-7
29.Raatikainen MJ, Peuhkurinen KJ, Hassinen IE. Contribution of endothelium and cardiomyocytes to hypoxia-induced adenosine release. J Mol Cell Cardiol. 1994; 26(8): 1069-80.
30.Fredholm BB, Sollevi A. Cardiovascular effects of adenosine. Clin Physiol. 1986; 6(1): 1-21
31.Kroll K, Bukowski TR, Schwartz LM, Knoepfler D, Bassingthwaighte JB Capillary endothelial transport of uric acid in guinea pig heart. Am J Physiol. 1992; 262(2 Pt 2): H420-31.
32.Castelli P, Condemi AM, Brambillasca C, Fundarò P, Botta M, Lemma M, Vanelli P, Santoli C, Gatti S, Riva E Improvement of cardiac function by allopurinol in patients undergoing cardiac surgery. J Cardiovasc Pharmacol. 1995; 25(1): 119-25.
33.Kogure K, Ishizaki M, Nemoto M, Kuwano H, Tatemoto K, Maruyama Y, et al. Evaluation of serum uric acid changes in different forms of hepatic vascular inflow occlusion in human liver surgeries. Life Sci. 1999; 64(5): 305-13.
34.Mathru M, Dries DJ, Barnes L, Sukhani R, Rooney MW. Tourniquet induced exsanquination in patients requiring lower limb surgery. An ischemia reperfusion model of oxidant and anti oxidant metabolism. Anesthesiology. 1996; 84:14-22
35.Anker SD, Leyva F, Poole-Wilson PA, Kox WJ, Stevenson JC, Coats AJ. Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure. Heart. 1997; 78(1): 39-43.
36.Cleland SJ, Petrie JR, Ueda S, Elliott HL, Connell JM. Insulin as a vascular hormone: implications for the pathophysiology of cardiovascular disease. Clin Exp Pharmacol Physiol. 1998; 25(3-4): 175-84.
37.Modan M, Halkin H. Hyperinsulinemia or increased sympathetic drive as links for obesity and hypertension. Diabetes Care. 1991; 14(6): 470-87.
38.Zweier JL, Kuppusamy P, Lutty GA. Measurement of endothelial cell free radical generation: evidence for acentral mechanism of free radical injuryin postischemic tissues. Proc Natl AcadSci. 1988; 85: 4046-50
39.Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction and vasoconstriction. Kidney Int. 2005; 67:1739-42
40.Ruggiero C, Cherubini A, Ble A, Bos AJ, Maggio M, Dixit VD., et al. Uric acid and inflammatory markers. Eur Heart J. 2006; 27: 1174-81.
41.Ruggiero C, Cherubini A, Miller E, Maggio M, Najjar SS, Lauretani F. et al. Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years. Am J Cardiol. 2007; 100: 115-121
42.Iliesiu A, Campeanu A, Dusceac D Serum uric acid and cardiovascular disease. Maedica (Buchar). 2010; 5(3): 186-92.
43.Hozawa A, Folsom AR, Ibrahim H, Nieto FJ, Rosamond WD, Shahar E, et al. Serum uric acid and risk of ischemic stroke: the ARIC study. Atherosclerosis. 2006; 187:401-407.
44.Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006; 54: 2688-2696.
45.Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Uric Acid and risk of myocardial infarction, stroke and congestive heart failure in 417734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Journal of Internal Medicine. 2009; 226: 558-570.
46.Jossa F, Farinaro E, Panico S, Krogh V, Celentano E, Galasso R, et al. Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens.1994; 8: 677–81.
47.Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med. 1980; 93: 817-821.
48.Puig JG and Ruilope LM. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens.1999; 17: 869-72.
49.Fried HP, Till GO, Trentz O, Ward PA. Role of oxygen radicals in tourniquet related ischemia-reperfusion injury of human patients. Klin Wochenschr. 1991; 69: 1109–12.
50.Feig DI, Kang DH, Johnson RG. Uric acid and Cardiovascular Risk, N Engl J Med. 2008; 359: 1811-1821.
51.Lee JE, Kim YG, Choi YO. Serum uric acid Is Associated with Microalbuminuria in Prehypertension. Hypertension. 2006; 47: 962-967.
52.Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal independent mechanism. Hypertension. 2001; 38: 1101-06.
53.M azzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism Am J Physiol Renal Physiol. 2002; 282: 991-997.
54.Watanabe S., Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, et al . Uric acid, hominoid evolution and the pathogenesis of salt-sensitivity. Hypertension. 2002; 40: 355-360
55.Sundström J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence in the Framingham Heart Study. Hypertension. 2005; 45: 28-33.
56.Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and Incidence of Hypertension Among Men Without Metabolic Syndrome. Hypertension. 2007; 49: 298-303.
57.Feig DI, Johnson RJ. Hyperuricemia in childhood essential hypertension. Hypertension. 2003; 42: 247-252.
58.Alper AB Jr, Chen W, Yau L, Srinivasan SR, Berenson GS, Hamm LL. Childhood Uric Acid Predicts Adult Blood Pressure: The Bogalusa Heart Study. Hypertension. 2005; 45: 34-38.
59.I Feig, B Soletsky, RJ Johnson. Effect of Allopurinol on Blood Pressure of Adolescents With Newly Diagnosed Essential Hypertension: A Randomized Trial. JAMA. 2008; 300(8): 924-32.
60.Hoeper MM, Hohlfeld JM, Fabel H. Hyperuricaemia in patients with right or left heart failure. Eur Respir J. 1999; 13: 682-685.
61.Campeanu A, Iliesiu A, Nistorescu D. Serum concentration of uric acid in patients hospitalized with chronic heart failure. Heart Failure Congress, Poster Session Berlin. 2010.
62.Lainscak M, von Haehling S, Anker SD. Natriuretic peptides and other biomarkers in chronic heart failure: From BNP, NT-proBNP, and MR-proANP to routine biochemical markers. International Journal of Cardiology. 2009; 3: 303-311.
63.Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, et al. Uric acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging. Circulation. 2003; 107: 1991-97.
64.Pascual-Figal DA, Hurtado-Martínez JA, Redondo B, Antolinos MJ, Ruiperez JA, Valdes M. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail. 2007; 9: 518-524
65.Alimonda AL, Núñez J, Núñez E, Husser O, Sanchis J, Bodí V, Miñana G, et al. Hyperuricemia in acute heart failure. More than a simple spectator? European Journal of Internal Medicine. 2009; 20: 74-9.
66.Ekundayo OJ, Dell'Italia LJ, Sanders PW, Arnett D, Aban I, Love TE, et al. Association between hyperuricemia and incident heart failure among older adults: Apropensity matched study. International Journal of Cardiology. 2010; 142: 279-87.
67.Krishnan E. Hyperuricemia and Incident Heart Failure. Circ Heart Fail. 2009; 2: 556-62
68.Lippi G, Montagnana M, Franchini M, Favaloro EJ, Targher G. The paradoxical relationship between serum acid uric and cardiovascular disease. Clinica Chimica Acta. 2008; 392: 1-7.
69.Høieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004; 65: 1041-1049.
70.Athyros VG, Elisaf M, Papageorgiou AA .Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) study. Am J Kidney Dis. 2004; 43: 589-599.
71.Farquharson CA, Butler R, Hill A. et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106: 221-226.
72.Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS, et al. Impact of oxypurinol in patients with symptomatic heart failure. J Am Coll Cardiol. 2008; 51: 2301-2309.
73.Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, Stevenson JC, Coats AJ. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997; 8: 858–865.
74.Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973–79.
75.Mustard JF, Murphy EA, Ogryzlo MA. Smythe HA. Blood coagulation and platelet economy in subjects with primary gout. Can Med Assoc J. 1963; 89: 1207–11.
76.Johnson WD, Kayser KL, Brenowitz JB, Saedi SF. A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J. 1991; 121: 20–24.
77.Tabayashi K, Suzuki Y, Nagamine S, Ito Y, Sekino Y, Mohri H. A clinical trial of allopurinol (Zyloric) for myocardial protection. J Thorac Cardiovasc Surg. 1991; 101: 713–718.
78.Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001;104: 2407–2411.
79.Waring WS, Webb DJ, Maxwell SRJ. Effect of local hyperuricemia on endothelial function in the human forearm vascular bed. Br J Clin Pharmacol. 2000b; 49: 511.
80.Kanabrocki EL, Third JL, Ryan MD, Nemchausky BA, Shirazi P, Scheving LE, et al Circadian relationship of serum uric acid and nitric oxide. JAMA. 2000; 283: 2240–41.
81.Santos CXC, Anjos EI, Augusto O. Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Arch Biochem Biophys. 1999; 372: 285–294.
82.Abuja PM. Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Lett. 1999; 446: 305–8.
83.Squadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu RM., et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys. 2000; 376: 333-7.
84.Hink HU, Santanam N, Dikalov S, McCann L, Nguyen AD, Parthasarathy S,. et al. Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol. 2002; 22: 1402–8.
85.Maples KR, Mason RP. Free radical metabolite of uric acid. J Biol Chem. 1988; 263: 1709-12.
86.Feig D I, Kang D H, Johnson R J. Uric Acid and Cardiovascular Risk. N Engl J Med. 2008 October 23; 359(17): 1811–1821.
87.George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114: 2508–16.
88.Waring WS, McKnight JA, Webb DJ, Maxwell SR. Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Diabetologia. 2007; 50: 2572–9.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Joshi M, Sodhi KS, Pandey R, Singh J, Goyal S. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Sireesha Srinivasa Rao1, Srinivas Rao Kuna2, Siva Kumar Chennam Setty3,*
Affiliation:-
1Associate Professor Psychiatry, Institute of mental health (IMH), Hyderabad, Telangana, India
2Civil Surgeon specialist, Department of Orthopedics, ESI Hospital, Sanathnagar, Hyderabad, Telangana, India
3Assistant Professor, Psychiatry, Institute of Mental Health (IMH), Hyderabad, Telangana, India
The name of the department(s) and institution(s) to which the work should be attributed:
1.Psychiatry, Institute of mental health (IMH),Hyderabad, Telangana,India
2.Department of Orthopedics, ESI Hospital, Sanathnagar, Hyderabad, Telangana, India
Address reprint requests to
Sireesha Srinivasa Rao.
Associate Professor Psychiatry, Institute of Mental Health, Yerragadda, Hyderabad, Telangana, India
Article citation:
Rao SS, Kuna SR, Setty SKC. A cross sectional study of psychiatric and physical morbidity among community dwelling urban elderly adults in Hyderabad, India J Pharm Biomed Sci. 2014; 04(11):1014-1024. Available at www.jpbms.info
ABSTRACT
Background and objectives: Age is an important determinant of psychiatric illness. The overall prevalence of mental and behavioural disorders tends to increase with age due to normal ageing of brain, deteriorating physical health and cerebral pathology .Disorders such as depression, anxiety, cognitive and psychotic disorders have a high prevalence among elderly. This study was planned to assess the prevalence and pattern of psychiatric morbidity, medical morbidities, sociodemographic factors associated.
Method: Cross-sectional study where urban elderly subjects were selected by random sampling technique, those who met inclusion criteria were assessed on MMSE,GHQ-30,MINI-plus,GDRS, and Modified Kuppuswamy scale for assessment of socioeconomic status.
Results: The prevalence of psychiatric morbidity amongst urban elderly was found to be 26% ,less in comparison to those reported in earlier studies from India. However the pattern of different disorders was found to be similar. Psychiatric morbidity was found to be more in female gender (76.9%), young old age group (61.52%), literates (84.59%), widowed /unmarried/single (61.52%), middle (38.21%) and low socioeconomic status (38.21%), nuclear families (69.12%). The Current study found statistically a significant association between psychiatric morbidity and age (p value=0.01), literacy (p value=0.02), marital status (p value=0.02), socioeconomic status (p value=0.02) and type of family (p value=0.02). 66.14% of elderly with psychiatric morbidity were found to have hypertension.
Conclusion: Larger studies carried over a longer period of time are recommended for future research. Geriatric clinics will prove helpful in early diagnosis of mental illness.
KEYWORDS: Elderly adults; psychiatric morbidity; physical illness.
REFERENCES
1.Anderson RJ, Freedland KE, Clouse RE, Lustman PJ.2001.The prevalence of comorbid depression in elderly adults with diabetes: a meta analysis. Diabetes Care. 24(6):1069-78.
2.Banker K, Prajapathi B and Kedia G.2011.Study of health profile of residents of geriatric home in Ahmedabad district. National Journal of community Medicine.2:378-82.
3.Banthia JK ,editor.2001.Census of India series I. NewDelhi: Controller of Publications. Appraisal of age data;p99.
4.Barua A, Ghosh MK, Kar N, Basilio MA. Sociodemographic factors of geriatric depression Indian J Psychological medicine. Med know publication obtained from www.science open.com /document vid/ 543be2a2 91d1-443-9315-6 searched on 3.9.2014.
5.Biswas SS, Gupta R, Vanjare HA, Bose S, Patel JA,Selvarajan 2009. Depression in elderly in Vellore, South India: the use of a two question screen. Int Psychogeriatr.21:369-71.
6.Carney RM . 2003. Depression as a risk factor for mortality after acute myocardial infarction. Am J Cardiology. 92(11):1277-81
7.Census of India .2011. Available from: http: //en.Wikipedia.org/wiki 2011 -census of India, Accessed on May 16th, 2014.
8. Chowdhary A,Rasania SK.2008. A community based study of psychiatric disorders among elderly living in Delhi .The Internet Journal of Health.7 (1).
9.Cole MG,Dendukuri N.2004.The feasibility and effectiveness of brief intervention to prevent depression in older subjects : a systemic review. Int J Geriatr Psychiatry.19:1019-25.
10.Desai A, Gross berg G. 2003. Differential diagnosis of psychotic disorders in the elderly: In Cohen CI editor. Schizophrenia in to later life: treatment, research and policy
Washington DC. American Psychiatric publishing, INC p55-78.
11.Folstein MF, Folstein SE, Mc Hugh PR.Mini-Mental status examination (MMSE).1975.A practical method for grading the cognitive state of the patients for the clinicians. J Psychiatr Res.12:189-98.
12.Goldberg DP. 1992.The detection of psychiatric illness by questionnaire. Maudsley monograph 21.London Oxford University press.
13.Jain RK ,Aras RY. 2007.Depression in geriatric population in urban slums in Mumbai. Indian J of Public Health.15:112-3.
14.Joshi K, Kumar R, Avasthi A.2003. Morbidity profile and its relationship with disability and psychological distress among elderly in Northern India. International J Epidemiology.32:978-87.
15.Lesperance F,Frasure-Smith N,Talajic M,Bourassa MG.2002.Five year riskof cardiac mortality in relation to initial severity and one year changes in depression symptoms after MI.Circulation.105(9):1049-53.
16.Levine JB . 1996. Psychological predictors of subsequent medical care among patients admitted with cardiac disease. J Cardio Pulmon Rehabil.16(2):109-16.
17.Mental health and ageing .ICMR bulletin 21;5:49-54.
18.Nandi PS, Banerji G, Mukherjee SP, Nandi S,Nandi DN.1997. A study of Psychiatric morbidity of elderly population of a rural community in West Bengal. Indian J Psychiatry.39:122-9.
19.Park editon.2011. Medicine and Social Sciences.Text book of Preventive and Social Medicine.21st edition: Jabalpur. In: Banarasi Das. Bhanot publishers.p 638-40.
20.Rajan SI .2003.Demography of ageing. In: Dey AB,editor Ageing in India: Situational analysis and planning in future. Ministry of health and family welfare-Govt of India Geneva: WHO.p 3-11.
21.Rajkumar S, Kumar S, Thara R. 1997. Prevalence of dementia in a rural setting: a report from India.Int J Geriatr Psychiatry.12:702-7.
22.Rajkumar AP, Thangadurai P, Senthil Kumar P.2009. Nature and prevalence and factors associated with depression among elderly in a rural south Indian community. International Psycho geriatrics.21:372-8.
23.Ritchie K ,Artero S, Beluche I .2004. Prevalence of DSM -IV Psychiatric disorder in French elderly population. Br J Psychiatry.184:147-52.
24.Seby K, Chaudhary S, Chakraborthy R .2011. Prevalence of psychiatric and Physical morbidity in urban geriatric population. Indian J Psychiatry .53:121-7.
25.Shaji K Arun kishore NR, Lal KP, Pinto C, Trivedi JK.2004. Better mental health care for older people in India. Indian J Psychiatry.46:367-72.
26.Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiler ET.1998 .The Mini-International Neuropsychiatric interview (MINI): The development and validation of a structured diagnostic Psychiatrici interview for DSM-IV and ICD-10 .J Clin Psychiatry.20:22-23.
27.Simonsick EM, Wallace RB, Blazer DG, Berkman LF . 1995. Depressive symptomatology and hypertension-associated morbidity and mortality in older adults. Psychosomatic med.57(5):427-35.
28.Tiwari S, Tripathi R . 2009. Neuropsychiatric morbidity amongst urban and rural elderlies in Northern India: Report from a community based epidemiological study. Int Psychogeriatr. 21(Suppl 2):s136.
29.Tiwari SC.2000. Gero Psychiatric morbidity in rural northern India: Implications for the future. Int Psychogeriatr.12:35-48.
30.Tiwari SC, Srivastava G, Tripathy.2013. Prevalence of psychiatric morbidity amongst the community dwelling rural older adults in North India. Indian J Med Res .138:504-14.
31.Vas CJ,Raj Kumar S, Tanya kitpisal R,Chandra V.2001. Alzheimer's disease: The Brain killer NewDelhi : WHO; p50.
32.Venkoba Rao A, Madhavan T. 1982. GeroPsychiatric morbidity survey in a semiurban area near Madhurai. Indian J Psychiatry. 24:258-62.
33.Yesavage JA, Brink TL, Rose TL, Lum O, Huang V,Adey M. 1983.Development and validation of a geriatric depression rating scale .A preliminary report. J Psychiatr Res.17:37-49.
34.Zayas E, Grossberg T. 1998. The treatment of psychosis in late life. J Clin Psychiatry.59:5-12.
Copyright © 2014 Rao SS, Rao SK, Chennamsetty SK. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript
Research article
Babafemi, E. O.1, David, O. M.1, Oluduro, A. O.2 and Famurewa, O.1,*
Affiliation:-
1Department of Microbiology University of Ado-Ekiti, Nigeria.P.M.B.5363, Ado-Ekiti, Nigeria.
2Department of Microbiology, ObafemiAwolowo University, Ile-Ife, Nigeria
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Microbiology, Ekiti State University, Ado-Ekiti, Nigeria, P.M.B. 5363, Ado-Ekiti, Nigeria
Department of Microbiology, Obafemi Awolowo University, Ile-Ife, Nigeria
Address reprint requests to
Famurewa, O.
Department of Microbiology Ekiti State University, Ado-Ekiti, Nigeria P.M.B. 5363, Ado-Ekiti, Nigeria
Article citation: Babafemi EO, David OM, Oluduro AO, Famurewa O. Epidemiology of methicillin-resistant Staphylococcus aureus among hospitalized patients and apparently healthy individuals in Ekiti and Ondo States, Nigeria. J Pharm Biomed Sci. 2014; 04(11):1025-1030. Available at www.jpbms.info
ABSTRACT
The incidence of methicillin-resistant Staphylococcus aureus (MRSA) in hospitalized patients and apparently healthy individuals was investigated in two western states of Nigeria using standard microbiological methods. One thousand and two hundred non-repeat isolates of S. aureus were recovered from the subjects. At varying degrees the isolates were resistant to cotrimoxazole (54.8%), augmentin (36.9%), pefloxacin (35.9%), gentamycin (28.3%), erythromycin (24.9%), vancomycin (10.3%), ofloxacin (5.2%) and ciprofloxacin (0.3%). One hundred and fifty six (13.0%) were resistant to methicillin out of which 4.8% and 8.2% were from healthy individuals and patients respectively. There was no correlation between prevalence of MRSA and age or sex (p < 0.05). There was no correlation between the antibiotic resistance pattern in MRSA from healthy volunteers and patients (P < 0.05). A total of 9.0%, 12.2% and 21.2% of the MRSA were resistant to 3, 4 and 5 antibiotics respectively. Antibacterial activities of five biocides examined using agar diffusion method showed that 38.5%, 53.2%, 59.6%, 61.5% and 71.8% of the MRSA were not inhibited by Izal®, Morigad®, Septol®, Dettol® and Purit® respectively, at concentrations two times higher than the in-use concentration. This finding points to the fact that MRSA occurs among patients and in the communities in the study areas, which calls for a public health concern and awareness.
KEYWORDS: Hospital-acquired MRSA; community acquired MRSA; biocides, epidemiology; multiple antibiotic resistance.
REFERENCES
1.Abraham B, Jacob G, Pablo Y, Nechawa P, Nurith P, Ronif T, Hannah S, Klaris R, Miriam S, Francis S. Community acquired MRSA in institutionalized adults with development disabilities. Emerg Infect Dis. 2002; 8:966-969.
2.Adeleke SI, Asani MO. Urinary tract infection with children with nephritic syndrome in Kano, Nigeria. Ann Afr Med. 2009; 8:38-41.
3.Ahmed MO, Elramalli AK, Amri SG, Abuzweda AR, Abouzeed YM. Isolation and screening of methicillin-resistant Staphylococcus aureus from health workers in Libyan hospitals. East Meditrr Health J. 2012; 18(1):37-42.
4.Ako-Nai AK, Ogunniyi AD, Lamikanra A, Torimiro SE. The characterisation of clinical isolates of Staphylococcus aureus in Ile-Ife, Nigeria. J Med Microbiol. 1991; 34:109-112.
5.Akujobi CN, Ilo IA, Egwuatu CC, Ezeanya CC. Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) among healthcare workers in a tertiary institution in Nigeria. Orient J Med. 2013; 25(3-4):82-87.
6.Anyanwu NCJ, Abdullahi IO, Ameh JB, Ella EE. Molecular detection of PVL, msrA genes and antibiotic susceptibility pattern of staphylococcus aureus from skin and soft tissue infections in Zaria, Nigeria. Scient J Microbiol. 2013: 2(2):43-52.
7.Ateba NU, Schaumburg F, Adegnika AA, Kosters K, Möller T, Fernandes JF, Alabi A, Issifou S, Becker K, Grobusch MP, Kremsner PG, Lell B. Epidemiology and population structure of Staphylococcus aureus in various population groups from a rural and semi urban area in Gabon, Central Africa. Acta Trop. 2012; 124:42-47.
8.Boyce JM. MRSA in hospitals and long term care facilities: microbiology, epidemiology and preventive measures. Infect Contr Hos Epidemiol. 2005; 13:725-734.
9.Castillo JA, Clapes P, Infante MR, Comas J, Manresa A. Comparative study of the antimicrobial activity of bis-(N{alpha}-caproyl-L-arginine)-1,3-propanediamine dihydrochloride and chlorhexidinedihydrochloride against Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother. 2006; 57:691-698.
10.Choi SC, Chow SY, Afra A. Nasal carriage of Staphylococcus aureus among healthy adults. J Microbiol Immunal Infect. 2006; 39:458-464.
11.Chopra I. Bacterial resistance to disinfectants, antiseptics and toxic metal ions. Soc Appl Bacteriol Tech Ser. 1991; 27:45-64.
12.CLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Eleventh Edition. M02-A11 32(1) Replaces M02-A10. 2012; 29(1).
13.Craig EZ, Bryon C, Mark AM, James EL, Adam A, Bruce KB. Community-acquired methicillin-resistant Staphylococcus aureus among Military Recruits. Emerg Infect Dis. 2004; 10:941-943.
14.David OM, Fakayode IB, Famurewa O. Evaluation of the anti-enterococcal activity of disinfectants and medicated soaps on vancomycin-resistant Enterococcus faecalis strains. Ann Res Rev Biol. 2014; 4(3):509-519.
15.David OM, Ayeni D, Fakayode IB, Famurewa O. Evaluation of antibacterial properties of various hand sanitizers wipes used for cosmetic and hand hygiene purposes in Nigeria. Microbiol Res Inter. 2013; 1(2): 22-26.
16.El-Mahmood AM, Doughari JH. Bacteriological examination of some diluted disinfectants routinely used in the Specialist Hospital Yola, Nigeria. Afr. J. Pharm Pharmacol. 2009; 3:185-1909.
17.Esan CO. Molecular studies of resistant Staphylococcus aureus in Ekiti and Ondo States, Nigeria. Ph.D Thesis. University of Ado-Ekiti, Nigeria. 2011.
18.Fawole MO, Oso BA. Laboratory Manual of Microbiology. Spectrum Books Limited, Ibadan. 2001; 127.
19.Fayyaz M, Mirza IA, Ahmed Z, Abbasi SA, Hussain A and Ali S. (). In vitro susceptibility of chloramphenicol against methicillin-resistant Staphylococcus aureus. J Coll Physic Surg Pak. 2013; 23(9): 637-640.
20.Fraise AP. Biocide abuse and antimicrobial resistance – A cause for concern? J Antimicrob Chemother. 2002; 49:1-12
21.Ghebremedhin B, Olugbosi MO, Raji AM, Layer F, Bakare RA, Konig B, Konig W. Emergence of a community-associated methicillin-resistant Staphylococcus aureus with unique resistance profile in Southwest of Nigeria. J Clin Microbiol. 2009; 47: 2975-2980.
22.Gilbert P, McBain AJ. Potential impact of increased use of biocides in consumer products on prevalence of antibiotic resistance. Clin Microbiol Rev. 2003; 16:189-208.
23.Holt JG, NR Krieg, PHA Sneath, JT Staley, and ST Williams. Bergey’s Manual of Determinative Bacteriology, 9th Edn. Williams & Wilkins, Baltimore. 1994.
24.Karpanen TJ, Worthington T, Hendry ER, Conway BR, Lambert PA. Antimicrobial efficacy of chlorhexidine digluconate alone and in combination with eucalyptus oil, tea tree oil and thymol against planktonic and biofilm cultures of Staphylococcus epidermidis. J Antimicrob Chemother. 2008; 325:1-6.
25.Kejela T, Bacha K. Prevalence and antibiotic susceptibility pattern of methicillin-resistant Staphylococcus aureus (MRSA) among primary school children and prisoners in Jimma Town, Southwest Ethiopia. Ann Clin Microbiol Antimicrob. 2013: 24: 12:11
26.Kesah C, Redjeb S.B., Odugbemi T.O., Boye C.S-B., Dosso M., NdinyaAchola J.O., Koulla-Shiro S, Benbachir M., Rahal K., Borg M (2003). Prevalence of methicillin-resistant Staphylococcus aureus in eight African hospitals and Malta. Clin.Microbiol. Infect. 9:153-156.
27.Kluytmans J, van Belkum A, Verbrugh H (1997). Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev. 10 (3): 505–20.
28.Kolman1, S, Arielly H, Paitan Y. Evaluation of single and double-locus real-time PCR assays for methicillin-resistant Staphylococcus aureus (MRSA) surveillance. BMC Res Notes. 2010; 3:110
29.Kumurya AS. Loss of the mecA gene during storage of methicillin-resistant Staphylococcus aureus isolates in Northwestern Nigeria. J Public Health Epidemiol. 2013; 5(10):410-415.
30.Little-John TG, Paulsen IT, Gillespie MT, Tennent JM, Midgley M, Jones IG. Substrate specificity and energetic of antiseptic and disinfectant resistance in Staphylococcus aureus. FEMS Letters. 1992; 95:259-266.
31.Monecke S, Ruppelt A, Wendlandt S, Schwarz S, Slickers P, Ehricht R, Jäckel SC. Genotyping of Staphylococcus aureus isolates from diseased poultry. Vet Microbiol. 2013; 162: 806-812.
32.Nadjia B, Mebrouk K. Phenotypic and genotypic characterization of Staphylococcus aureus agents of dairy cows’ mastitis in Algeria. J Appl Sci Res. 2013; 9(1):86-93.
33.Noguchi N, Nakaminami H, Nishijima S, Kurokawa I, So H, Sasatsu M. Antimicrobial agent of susceptibilities and antiseptic resistance gene distribution among methicillin-resistant Staphylococcus aureus isolates from patients with impetigo and staphylococcal scalded skin syndrome. J Clin Microbiol. 44: 2119-2125.
34.Noguchi N, Suwa J, Narui K, Sasatsu M, Ito T, Hiramatsu K, Song JH. Susceptibilities to antiseptic agents and distribution of antiseptic-resistance genes qacA/B and smr of methicillin-resistant Staphylococcus aureus isolated in Asia during 1998 and 1999. J Med Microbiol. 2005; 54:557-565.
35.Nwakwo BOK, Abdulhadi S, Magagi A, Ihesiulor G. Methicillin resistant Staphylococcus aureus and their antibiotic susceptibility pattern in Kano, Nigeria. Afr J Clin Experim.Microbiol. 2010; 11(1):1595-689.
36.Ebrahimi A, Ghasemi M, Ghasemi B. Some Virulence Factors of Staphylococci Isolated From Wound and Skin Infections in Shahrekord, IR Iran. Jundishapur J Microbiol. 2014; 7(4):1-5.
37.Obajuluwa AF, Onaolapo JA, Oyi AR, Olayinka BO. Susceptibility profile of methicillin-resistant Staphylococcus aureus (MRSA) Isolates to antibiotics and methanolic extracts of parkia biglobosa (Jacq) Benth. Brit J Pharma Res. 2013; 3(4):587-596.
38.Odetoyin WB, Aboderin AO, Ikem RT, Kolawole BA, Oyelese AO. Asymptomatic bacteriuria in patients with diabetes mellitus in Ile-Ife, South-West, Nigeria. East Afr Med J. 2008; 85:18-23.
39.Olutiola PO, Famurewa O, Sonntag H-G. An Introduction to General Microbiology.Hygiene-Institut Der Universitat Heidelberg Federal Republic of Germany. 2001; 267.
40.Onemu OS, Ophori EA. Prevalence of multi-drug resistant Staphylococcus aureus in clinical specimens obtained from patients attending the University of Benin Teaching Hospital, Benin City, Nigeria. J Nat Sci Res. 2013; 3(5):154-159.
41.Onochie CC, Chukwudi A, Alo MN, Onwa NC, Okonkwo EC and Afiukwa FN. Bacteriological examination of computer keyboards and mouse devices and their susceptibility patterns to disinfectants. Amer J Microbiol. 2013; 4(1):9-19.
42.Pallin DJ, Egan DJ, Pelletier AJ, Espinola JA, Hooper DC, Camargo CA. Increased US Emergency Department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin- resistant Staphylococcus aureus. Ann Emerg Med. 2008; 51:291-298.
43.Popovich KJ, Weinstein RA, Hota B. Are community-associated methicillin- resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis. 2008; 46:787-794.
44.Price CS, Williams A, Philips G, Dayton M, Smith W, Morgan S. Staphylococcus aureus nasal colonization in pre-operative orthopaedic out patients. Clin Orthop Relat Res. 2008; 466:2824-2847.
45.Ramdani-Bouguessa N, Bes M, Meugnier H, Forey F, Reverdy ME, Lina G, Vandenesch F, Tazir M, Etienne J. Detection of methicillin-resistant Staphylococcus aureus strains resistant to multiple antibiotics and carrying the Panton-Valentine leukocidin genes in an Algiers hospital. Antimicrob Agents Chemother. 2006; 50:1083-1085.
46.Sheikh AF, Mehdinejad M. Identification and determination of coagulase-negative Staphylococcus species and antimicrobial susceptibility pattern of isolates from clinical specimens. Afri J Microbiol Res. 2012; 6(8):1669-1674.
47.Shittu AO, Lin J, Kolawole DO. Antimicrobial susceptibility patterns of Staphylococcus aureus and characterization of MRSA in Southwestern Nigeria. Wounds. 2006; 18:77-84
48.Shittu AO, Lin J. Antimicrobial susceptibility pattern and characterization of clinical isolates of Staphylococcus aureus in Kwazulu-Natal province of South Africa. BMC Infect Dis 2006; 6:188-192.
49.Smith TL, Pearson ML, Wilcox KR. Emergence of Vancomycin resistance in Staphylococcus aureus. NEJM. 1999; 340:493-501.
50.Tula MY, Azih AV, Okojie RO. Antimicrobial susceptibility pattern and plasmid-mediated antibacterial resistance in Staphylococcus aureus and coagulase-negative staphylococci (CoNS). Amer J Res Com. 2013; 1(9):149-166.
51.Weber DJ, Rutala WA, Sickbert-Bennett EE. Outbreaks associated with contaminated antiseptics and disinfectants. Antimicrob Agents Chemother. 2007; 51:4217-4224.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © Babafemi EO, David OM, Oluduro AO, Famurewa O. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Gulati Deepti1* and Goyal Pallavi2
Affiliation:-
1Senior Lecturer, 2Graduate, Department of Biotechnology, Dolphin (PG) Institute of Biomedical & Natural Sciences, Dehra Dun-248007, Uttarakhand, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Biotechnology, Dolphin (PG) Institute of Biomedical & Natural Sciences, Dehra Dun-248007, Uttarakhand, India
Address reprint requests to
Deepti Gulati,
House No. 5/12/3, Prem Nagar, Dehra Dun, Uttarakhand-248007,India
Article citation: Gulati D, Goyal P. Identification and multiple drug resistance of bacteria Isolated from soil samples collected from pharmaceutical industrial Area. J Pharm Biomed Sci. 2014; 04(11):984-994. Available at www.jpbms.info
ABSTRACT
The present study was aimed to determine Multiple-Drug Resistance among the isolated bacterial populations. The antibiotic sensitivity test was performed against 8 different antibiotics for the 16 bacterial strains isolated from Industrial area, Selaqui, Dehra Dun. All the strains were identified by Gram staining and Biochemical tests. They included; Pseudomonas sp., Bacillus sp., Klebsiella sp., Proteus sp., Staphylococcus sp., Streptococcus sp. and Enterococcus sp. The antibiotics used in the study were Penicillin (10μg), Neomycin (30μg), Cefotaxime (10μg), Rifampicin (2μg), Streptomycin(10μg), Cotrimoxazole(25μg),Amoxicillin(10μg) and Ciprofloxacin (10μg). Most of the isolates were found to be resistant to Rifampicin and Penicillin. 62.5% of the isolates were found to be resistant to Rifampicin, 56.25% to Penicillin, 12.5% to Neomycin, 12.5% to Cotrimoxazole, 6.25% to Streptomycin, 6.25% to Amoxycillin and 6.25% to Ciprofloxacin. None of the isolates was found to be resistant to Cefotaxime. The results of the study showed Rifampicin to be the least effective medicine and Cefotaxime to be the most effective medicine.
KEYWORDS: Antibiotic sensitivity; Multiple-drug resistance; Pharmaceutical effluent.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
REFERENCES
1.Benotti and Etho (2008). Pharmaceuticals as Tracers of Municipal Waste water in Urban Estuaries. (BEN – 117 – 831465).
2. Roth, C; Dong, Z., Senn, D., Maclead, M. & Shine, J. (2005). Transport and Fate of Selected Priority Pharmaceuticals in U.S. Harvard University, Boston, MANAGEMENT USA Swiss Federal Institute of Technology, Zurich, Switzerland. (ROT – 117 – 834293).
3.Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria: an update. Drugs.2009;69 (12): 1555–623.
4.Stix G . An antibiotic resistance fighter. Sci. Am. 2006;294(4): 80–3.
5.Bauer, AW, Kirby WM, Sherris JC and Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am. J. Clin. Pathol. 1966;45: 493-496.
6.DebMandal Manisha, Mandal Shyamapada and Kumar Pal Nishith. Antibiotic resistance prevalence and pattern in environmental bacterial isolates. The open antimicrobial agents’ journal.2011; 3:45-52.
7.Amit Pandey, Afsheen, Firdous Ara, Sudeep Kumar Tiwari. Isolation and characterization of multi drug resistance cultures from waste water. Journal of Pharmaceutical and Biomedical Sciences (J Pharm Biomed Sci). 2011:13(14). Accessed from www.jpbms.info
8.Sahaab Farooq, Ifra Ghori and Faiqa Abdur Rub (2013). “Identification and multiple drug resistance of bacteria, isolated from pharmaceutical industrial effluent (Islamabad, Pakistan)”. Int J Curr Sci. 2013;6:E 125-132.
9.Chaturvedi Sonal, Chandra Ram and Rai Vibhuti (2008). “Multiple antibiotic resistance patterns of rhizospheric bacteria isolated from Phragmites australis growing in constructed wetland for distillery effluent treatment”. J. Environ. Biol.2008;29(1):117 124.
Copyright © Gulati D,Goyal P. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.